The primary endpoint is objective response rate is determined by an independent review facility. Secondary endpoints include duration of response, progression-free survival, overall survival and tolerability. The company plans to participate in patients with more than 30 locations in the U.S., Canada and Europe.. The single-arm phase II the efficacy and safety the efficacy and safety of single agent SGN-35 in 55 patients with relapsed or refractory systemic ALCL. In the U.S.eceived 1.8 milligrams per kilogram of SGN-35 every three weeks.
SGN-35 is an antibody-drug conjugate , Seattle Genetics ‘ proprietary technology is used to enhance antibody by. Effective cell-killing drugs ‘We have promising activity in ALCL patients observed in our Phase I clinical trials, in particular six of seven patients treated with SGN-35, a complete remission,’said Clay B. Siegall, President and Chief Executive Officer Seattle Genetics. ‘SGN-35 could be an important therapeutic option for patients who are relapsed to the to the standard front-line chemotherapy, and we believe that ALCL ALCL offer an additional registration pathway for SGN-35.’..Of these patients,ts from TNFerade Head Neck Cancer Study presented at the ASCO.
Encouraging dates GenVec ‘ southeast phase of I clinical trial of TNFerade patients with head and neck tumors were presented to by lead investigator About Vokes Vokes, the University of Chicago, into a poster session at the annual convention the American Society of Clinical Oncology in Chicago.